Safety and efficacy of a probiotic cocktail containing P. acidilactici and L. plantarum for gastrointestinal discomfort in endurance runners: randomized double-blinded crossover clinical trial

• Published in: Applied physiology, nutrition, and metabolism nutrition, and metabolism, 2024-07, Vol.49 (7), p.890-903
• Main Authors: Lennon, Sarah, Lackie, Thomas, Miltko, Adriana, Kearns, Zoey C, Paquette, Maxime R, Bloomer, Richard J, Wang, Anyou, van der Merwe, Marie
• Format: Article
• Language: English
• Subjects: Acute-Phase Proteins; Adult; Aspartate Aminotransferases - blood; Athletes; Carrier Proteins; Cross-Over Studies; Cytokines - blood; Digestive system; Double-Blind Method; Fatty Acid-Binding Proteins - blood; Feces - microbiology; Female; Gastrointestinal Diseases; Gastrointestinal Microbiome; Haptoglobins; Humans; Lactobacillus plantarum; Male; Marathons; Membrane Glycoproteins; Middle Aged; Pediococcus acidilactici; Permeability; Physical Endurance; Probiotics; Probiotics - administration & dosage; Protein Precursors - blood; Running - physiology; Young Adult
• ISSN: 1715-5312; 1715-5320; 1715-5320
• DOI: 10.1139/apnm-2023-0449

Probiotics are increasingly used to treat conditions associated with gastrointestinal injury and permeability, including exercise-induced gastrointestinal discomfort. This study assessed safety and efficacy of a probiotic in altering the intestinal milieu and mitigating gastrointestinal symptoms (GIS) in endurance runners. In a double blind, crossover study, 16 runners were randomized to 4 weeks of daily supplementation with a probiotic cocktail containing bacteria and or placebo. Fasting blood and stool samples were collected for measurement of gut permeability markers, immune parameters, and microbiome analyses. Treadmill run tests were performed before and after treatment; participants ran at 65%-70% of VO at 27 °C for a maximum of 90 min or until fatigue/GIS developed. A blood sample was collected after the treadmill run test. In healthy individuals, 4 weeks of probiotic supplementation did not alter health parameters, although a marginal reduction in aspartate aminotransferase levels was observed with probiotic treatment only (  = 0.05). GIS, gut permeability-associated parameters (intestinal fatty acid binding protein, lipopolysaccharide binding protein, zonulin, and cytokines), and intestinal microbial content were not altered by the probiotic supplementation. Post-run measurements of GIS and gut-associated parameters did not differ between groups; however, the observed lack of differences is confounded by an absence of measurable functional outcome as GIS was not sufficiently induced during the run. Under the current study conditions, the probiotic was safe to use, and did not affect gut- or immune-associated parameters, or intestinal symptoms in a healthy population. The probiotic might reduce tissue damage, but more studies are warranted.